key: cord-0857479-0yhab8bl
authors: Ramnath, Venktesh R.; McSharry, David G.; Malhotra, Atul
title: Do No Harm: Reaffirming the Value of Evidence and Equipoise While Minimizing Cognitive Bias in the Coronavirus Disease 2019 Era
date: 2020-05-28
journal: Chest
DOI: 10.1016/j.chest.2020.05.548
sha: 98bcf594ff2756db34506fdbbb174eb821d53c70
doc_id: 857479
cord_uid: 0yhab8bl

nan

The coronavirus disease 2019 (COVID-19) pandemic has tested the mettle of critical care practitioners worldwide by raising anxieties about how best to battle the disease. Notably, the pandemic has exposed the fragility of belief in longstanding medical evidence, equipoise with novel therapies, and objective rationales in medical decision-making, all of which underpin the principle of primum no nocere ("do no harm").

The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) illness parallels that of other virulent respiratory viruses may not be widely recognized. Although the data are still evolving, SARS-CoV-2 causes ARDS with lower severity of illness on presentation 1 and case mortality projections that slightly exceed those of influenza. SARS-CoV-2 matches the transmissibility through droplets of the influenza A virus (H1N1) and seasonal influenza, human metapneumovirus, adenovirus, and other respiratory viruses causing their own yearly fatalities. Protective measures, including social distancing, maskwearing, and hand hygiene, effectively reduce infection rates from all respiratory viruses. In fact, the recent drop in influenza attack rates in Japan was directly attributed to mitigation measures adopted for control of SARS-CoV-2. Finally, although some initially suggested that a new phenotype of ARDS due to SARS-CoV-2 (COVID-19 ARDS) required attention, 2 consensus now converges on COVID-19-related ARDS instead lying within the spectrum of known inflammatory lung disease and existing definitions of ARDS (eg, Berlin criteria 3 ), which are best managed by using decades-long understanding and experience. In other words, COVID-19 pneumonia seems to be a more sinister version of diseases that most clinicians already understand well.

On the front lines of COVID-19, however, unproven therapies have been used under an "off-label" rubric. Examples include the use of hydroxychloroquine, lopinavir/ritonavir, tocilizumab, early use of steroids, convalescent plasma, and others. With some exceptions (eg, remdesivir 4 ), most therapies lack significant benefit to date and are associated with potential or actual harm. 5, 6 As such, the use of these therapies cautions us to reflect on a possible role of cognitive biases in medical decision-making 7 (Table 1) . For example, the high acuity and slow course of severe COVID-19 cases make us vulnerable to both information bias (the tendency to make associations based on incomplete or inaccurately measured data) and action bias (the feeling that "doing something" is inherently better than "doing nothing"). Fragmented information available through social media and mainstream media outlets can cause anchoring and framing effects based on how data are presented and received that can further complicate objective evaluation. Representativeness bias may label all patients with acute respiratory failure as having COVID-19, and premature closure can deprioritize other diagnoses (eg, potential coexistent pulmonary embolism), while overconfidence and confirmation bias may unconsciously reinforce the decisions we make. As a result, complications can occur. First, use of medications with lower thresholds of scrutiny can actually hurt patients. Hydroxychloroquine use is now restricted due to concerns of life-threatening cardiotoxicities in COVID-19 patients. 8 Steroids are associated with variable mortality, although increased mortality was seen in influenza pneumonia. 9 Although one retrospective study among patients with COVID-19 ARDS suggested that treatment with methylprednisolone decreased risk of death, 10 prospective studies are necessary to make definitive conclusions. Calls to avoid angiotensin-converting enzyme inhibitors have complicated attempts to control hypertension and cardiac disease that can cause immediate detrimental effects. 11 Second, "compassionate use" of unproven therapies can be ethically challenging for patients, families, and practitioners. Risks include exacerbating inequities inherent to gaining access to such medications and experiencing disappointment when putative benefits become impossible to confirm and may even prolong suffering. 12 Third, unregulated use of unproven therapies, most notably hydroxychloroquine, has reduced supplies and hampered access to treatments with proven benefit for rheumatologic and malarial diseases affecting millions of people. 13 14 that show outcome improvements from years of careful study in patients who are ventilated. Finally, anecdotal use of off-label medications hinders equipoise to perform proper clinical trials that could make true scientific advancements. By adopting reflection and humility in how we use available therapies, physicians can bolster efforts against antivaccine, anti-brain death, and other challenges to medical wisdom that already suggest an ebbing of public trust in medical science in the United States.

Clinicians can reset the balance in a number of ways. First, an awareness of our innate tendencies to exhibit cognitive biases is essential. Although a purely objective approach is difficult, we must apply ourselves to selfcritique and open, active discussions with colleagues about the strengths and limitations of available data prior to using putative therapies. Actions that diminish Consider quality in addition to the quantity of evidence chestjournal.org equipoise should be viewed as exceptions rather than norms. Second, we must restrict unproven therapies to clinical trials to protect equipoise. Despite our best intentions, every off-label use of an unproven therapy may dent the research-based edifice upon which medical science rests. Instead, we can channel this energy to develop collaborative relationships with academic and industry partners to enroll more patients into clinical trials. Third, clinicians must remember that medicine is an inductive (not deductive) science and therefore cannot delivery 100% diagnostic certainty even under "perfect" conditions.

Medicine often delivers reliable and positive results when therapies based on rigorous scientific evidence such as randomized controlled trials are adopted as standards of care. Indeed, because COVID-19 patients often require prolonged ventilator management, we must ensure that ARDS is accurately diagnosed and treated appropriately. 15 Finally, clinicians should practice cautious optimism, vigilance, and a strong sense of humility, knowing that COVID-19 is just the latestnot the last-medical crisis for mankind. Such approaches will positively affect our efforts to combat COVID-19 and other global medical threats, such as the escalating prevalence of antibiotic-resistant bacteria. By following these strategies, critical care clinicians will not only better steer patients away from harm but also reinvigorate and sustain the scientific progress.

Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1

Management of COVID-19 respiratory distress

Interobserver reliability of the Berlin ARDS definition and strategies to improve the reliability of ARDS diagnosis

NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19

In defense of evidence-based medicine for the treatment of COVID-19 ARDS

Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report

Cognitive biases associated with medical decisions: a systematic review

FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems

Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study

Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

An analysis of common ethical justifications for compassionate use programs for experimental drugs

Why hoarding of hydroxychloroquine needs to stop

Caring for critically ill patients with the ABCDEF bundle: results of the ICU liberation collaborative in over 15,000 adults

A critical care clinician survey comparing attitudes and perceived barriers to low tidal volume ventilation with actual practice